Cetirizine Hydrochloride Syrup (Cetirizine Hydrochloride Oral Solution, USP) 1 mg/mL, 120 mL and ...
FDA Drug Recall #D-394-2014 - Class III, December 16, 2013
Recall Summary
| Recall Number | D-394-2014 |
| Classification | Class III, Low risk |
| Date Initiated | December 16, 2013 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Qualitest Pharmaceuticals |
| Location | Huntsville, AL |
| Product Type | Drugs |
| Quantity | 438,055 bottles |
Product Description
Cetirizine Hydrochloride Syrup (Cetirizine Hydrochloride Oral Solution, USP) 1 mg/mL, 120 mL and 480 mL bottles, Rx only. Mfg. for: Qualitest Pharmaceuticals, Huntsville, AL 35811. NDC 0603-9063-54 (120 mL), NDC 0603-9063-58 (480 mL).
Reason for Recall
Failed impurities/degradation specifications; out of specification for the known impurity 4-chlorobenzophenone.
Distribution Pattern
Nationwide and Puerto Rico
Lot / Code Information
Lot Numbers: NDC 0603-9063-54 (120 mL): L081K12A, exp. 4/14; L082K12A, exp. 4/14; L062M12A, exp. 6/14; L063M12A, exp. 6/14; L064M12A, exp. 6/14; L054A13A, exp. 7/14; L055A13A, exp. 7/14; L057A13A, exp. 7/14; L058A13A, exp. 7/14; L075B13A, exp. 8/14; L076B13A, exp 8/14; L003C13A, exp. 8/14; L004C13A, exp. 8/14; and L005C13A, exp. 8/14 NDC 0603-9063-58 (480 mL): L081K12B, exp. 4/14; L082K12B, exp. 4/14; L059A13A, exp. 7/14; L114E13A, exp. 10/14; L026G13A, exp. 12/14; and L081J13A, exp. 3/15.
Other Recalls from Qualitest Pharmaceuticals
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-1405-2015 | Class III | ALLOPURINOL TABLETS, USP, 300 mg, 500 count bot... | Jul 20, 2015 |
| D-1239-2015 | Class III | HydrOXYzine Hydrochloride Tablets, USP 25 mg, ... | Jun 29, 2015 |
| D1151-2015 | Class III | Disulfiram tablets, USP, 500 mg, 100-count bott... | Jun 18, 2015 |
| D00432-2015 | Class III | PROMETHAZINE VC WITH CODEINE SYRUP, EACH 5 ml c... | Mar 25, 2015 |
| D-0411-2015 | Class II | PROMETHAZINE DM SYRUP (Promethazine Hydrochlori... | Feb 23, 2015 |
Frequently Asked Questions
Nitrosamines are probable human carcinogens, they can increase cancer risk with long-term exposure above certain thresholds, but they do not cause immediate harm from taking a single dose. The FDA calculates an acceptable daily intake (ADI) for each nitrosamine compound, and recalls are triggered when levels exceed this threshold. If you have been taking a recalled product, the FDA generally advises against abruptly stopping your medication (especially for critical conditions like blood pressure or diabetes) until you consult your doctor. The incremental cancer risk from short-term exposure is very small.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications, even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications, use a drug take-back program.